n(g),n(g')-dimethyl-l-arginine has been researched along with Proteinuria in 15 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients." | 9.14 | Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010) |
| "Proteinuria is an independent risk factor for cardiovascular disease (CVD) in patients with chronic kidney disease (CKD)." | 5.38 | Proteinuria elevates asymmetric dimethylarginine levels via protein arginine methyltransferase-1 overexpression in a rat model of nephrotic syndrome. ( Ando, R; Fukami, K; Iwatani, R; Kaida, Y; Nakayama, Y; Okuda, S; Ueda, S; Yamagishi, S, 2012) |
| "Ramipril was given (5 mg daily for 12 weeks), and circulating ADMA, soluble Fas (sFas), myostatin and endothelial function [flow-mediated vasodilation (FMD); ultrasound)] were measured." | 5.36 | Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? ( Axelsson, J; Caglar, K; Cayci, T; Eyileten, T; Kilic, S; Oguz, Y; Saglam, M; Sonmez, A; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2010) |
| "Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients." | 5.14 | Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010) |
| "In patients with T2D, hypertension and overt nephropathy, the renoprotection afforded by telmisartan and valsartan appears similar, and the study was unable to show any effect beyond that due to blood pressure control." | 5.13 | Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. ( Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C, 2008) |
| " Covariates that were considered for adjustment included clinical characteristics, baseline GFR (Modification of Diet in Renal Disease equation 7 formula), proteinuria, traditional cardiovascular risk factors, serum C-reactive protein, homocysteine, and concomitant therapies." | 3.73 | Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. ( Malberti, F; Mallamaci, F; Ravani, P; Testa, S; Tripepi, G; Zoccali, C, 2005) |
| "The rationale of this study is based on the fact that, both proteinuria and elevated asymmetric dimethyl arginine (ADMA) levels have been linked to the progression of vascular disease." | 3.73 | ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. ( Acikel, C; Bilgi, C; Caglar, K; Cakir, E; Eyileten, T; Kaya, A; Oguz, Y; Oktenli, C; Sonmez, A; Vural, A; Yenicesu, M; Yilmaz, MI; Zoccali, C, 2006) |
| "Proteinuria is an independent risk factor for cardiovascular disease (CVD) in patients with chronic kidney disease (CKD)." | 1.38 | Proteinuria elevates asymmetric dimethylarginine levels via protein arginine methyltransferase-1 overexpression in a rat model of nephrotic syndrome. ( Ando, R; Fukami, K; Iwatani, R; Kaida, Y; Nakayama, Y; Okuda, S; Ueda, S; Yamagishi, S, 2012) |
| "Ramipril was given (5 mg daily for 12 weeks), and circulating ADMA, soluble Fas (sFas), myostatin and endothelial function [flow-mediated vasodilation (FMD); ultrasound)] were measured." | 1.36 | Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? ( Axelsson, J; Caglar, K; Cayci, T; Eyileten, T; Kilic, S; Oguz, Y; Saglam, M; Sonmez, A; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Saka, MH | 1 |
| Madi, NM | 1 |
| Ibrahim, RR | 1 |
| Alghazaly, GM | 1 |
| Elshwaikh, S | 1 |
| El-Bermawy, M | 1 |
| Sasser, JM | 1 |
| Cunningham, MW | 1 |
| Baylis, C | 2 |
| Alpoim, PN | 1 |
| Sousa, LP | 1 |
| Mota, AP | 1 |
| Rios, DR | 1 |
| Dusse, LM | 1 |
| Garsen, M | 1 |
| Rops, AL | 1 |
| Li, J | 1 |
| van Beneden, K | 1 |
| van den Branden, C | 1 |
| Berden, JH | 1 |
| Rabelink, TJ | 1 |
| van der Vlag, J | 1 |
| Nakamura, T | 1 |
| Sato, E | 1 |
| Fujiwara, N | 1 |
| Kawagoe, Y | 1 |
| Ueda, Y | 1 |
| Suzuki, T | 1 |
| Ueda, S | 2 |
| Fukami, K | 2 |
| Okuda, S | 2 |
| Yamagishi, S | 2 |
| Yilmaz, MI | 4 |
| Sonmez, A | 4 |
| Saglam, M | 3 |
| Yaman, H | 1 |
| Cayci, T | 1 |
| Kilic, S | 1 |
| Eyileten, T | 4 |
| Caglar, K | 4 |
| Oguz, Y | 4 |
| Vural, A | 4 |
| Yenicesu, M | 4 |
| Axelsson, J | 2 |
| Grassi, G | 1 |
| Seravalle, G | 1 |
| Ghiadoni, L | 1 |
| Tripepi, G | 2 |
| Bruno, RM | 1 |
| Mancia, G | 1 |
| Zoccali, C | 3 |
| Kaida, Y | 1 |
| Nakayama, Y | 1 |
| Ando, R | 1 |
| Iwatani, R | 1 |
| Wagner, L | 1 |
| Riggleman, A | 1 |
| Erdely, A | 1 |
| Couser, W | 1 |
| Ravani, P | 1 |
| Malberti, F | 1 |
| Testa, S | 1 |
| Mallamaci, F | 1 |
| Cakir, E | 3 |
| Kaya, A | 1 |
| Acikel, C | 2 |
| Bilgi, C | 1 |
| Oktenli, C | 1 |
| Kielstein, JT | 1 |
| Fliser, D | 1 |
| Kurt, Y | 1 |
| Tasar, M | 1 |
| Qureshi, AR | 1 |
| Carrero, JJ | 1 |
| Lindholm, B | 1 |
| Stenvinkel, P | 1 |
| Galle, J | 1 |
| Schwedhelm, E | 1 |
| Pinnetti, S | 1 |
| Böger, RH | 1 |
| Wanner, C | 1 |
1 review available for n(g),n(g')-dimethyl-l-arginine and Proteinuria
| Article | Year |
|---|---|
Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
Topics: Arginine; Cardiovascular Diseases; Humans; Kidney Diseases; Kidney Transplantation; Nitric Oxide; Ni | 2015 |
3 trials available for n(g),n(g')-dimethyl-l-arginine and Proteinuria
| Article | Year |
|---|---|
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Arginine; Azetidines; Cholesterol; Cho | 2010 |
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; | 2007 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pre | 2008 |
11 other studies available for n(g),n(g')-dimethyl-l-arginine and Proteinuria
| Article | Year |
|---|---|
The ameliorative effect of angiotensin 1-7 on experimentally induced-preeclampsia in rats: Targeting the role of peroxisome proliferator-activated receptors gamma expression & asymmetric dimethylarginine.
Topics: Angiotensin I; Animals; Arginine; Blood Pressure; Female; Oxidative Stress; Peptide Fragments; Place | 2019 |
Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Arginine; Arterial Pressure; Dinopro | 2014 |
Endothelial Nitric Oxide Synthase Prevents Heparanase Induction and the Development of Proteinuria.
Topics: Albumins; Animals; Arginine; Doxorubicin; Enzyme Induction; Gene Expression Regulation, Enzymologic; | 2016 |
Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Arginine; Chronic Disease; Diabetic Nephropat | 2010 |
Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Chronic Disease; Cross-Sectional Studies; Disease Pro | 2011 |
Proteinuria elevates asymmetric dimethylarginine levels via protein arginine methyltransferase-1 overexpression in a rat model of nephrotic syndrome.
Topics: Acetylcysteine; Animals; Antioxidants; Arginine; Cells, Cultured; Disease Models, Animal; Doxorubici | 2012 |
Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis.
Topics: Animals; Antibodies; Arginine; Autoantibodies; Blood Urea Nitrogen; Creatinine; Glomerulonephritis; | 2002 |
Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
Topics: Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular System; Cohort Studies; Dialysis; Dis | 2005 |
ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease.
Topics: Adult; Arginine; Biomarkers; C-Reactive Protein; Case-Control Studies; Chronic Disease; Disease Prog | 2006 |
Lowering asymmetric dimethylarginine--a new mechanism mediating the renoprotective effects of renin-angiotensin system inhibitors in proteinuric patients?
Topics: Amidohydrolases; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2007 |
ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.
Topics: Adult; Amyloidosis; Arginine; Chronic Disease; Endothelium; Female; Glomerulonephritis; Humans; Male | 2008 |